Recurrent endometrial stromal sarcoma in the abdominal wall following a total hysterectomy: A rare case report
Autor: | Kade Yudi Saspriyana, Sigit Purbadi |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
medicine.medical_treatment Navel Article Abdominal wall 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Case report medicine Endometrial stromal sarcoma Wide excision Chemotherapy Hysterectomy Uterine sarcoma business.industry Guideline medicine.disease Carboplatin Surgery medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Reconstruction Recurrent business |
Zdroj: | International Journal of Surgery Case Reports |
ISSN: | 2210-2612 |
DOI: | 10.1016/j.ijscr.2020.03.003 |
Popis: | Highlights • High-grade endometrial stromal sarcoma (HG-ESS) behaves in a more aggressive manner with a poorer overall prognosis than low-grade ESS. • Recurrence develops in one-half to two-third of patients with High-grade endometrial stromal sarcoma. • The major therapeutic procedure of patients with single site recurrent HG-ESS is primarily surgical resection. • Interdisciplinary and interprofessional teamwork are important in management of recurrent HG-ESS. Introduction High-grade endometrial stromal sarcoma (HG-ESS) is a rare pathological type of uterine sarcoma. Over 80 % of affected patients would experience recurrences within a few years of initial presentation. Such case is rare and therefore, we need to report the case including the management. Information on performing good surgical techniques is important. Case presentation A 55-year-old female patient was referred after having a total hysterectomy and bilateral salphingoophorectomy at a private hospital. Results of pathologic examination showed that the patient had HG-ESS. The patient subsequently received adjuvant chemotherapy. The regimens used were Carboplatin (AUC-6) and Paclitaxel (175 mg/m2). Within five months following the chemotherapy, she complained rapid abdominal enlargement, which was a clinically mobile palpable solid mass at the level of the navel. Imaging findings suggested recurrent endometrial stromal sarcoma in the abdominal wall. Wide excision and frozen section, which were continued with mesh insertion and abdominal wall reconstruction, were then performed. Discussion Recurrence develops in one-half to two-third of patients with HG-ESS. It has been reported that the sites of recurrence usually include multiple lung metastases, peritoneal metastases, and/or local recurrences. There is currently no standard therapy for patients with recurrence of the disease as HG-ESS is a rare clinical entity. Treatment has been defined based on experiences gained from retrospective case reports. Conclusion Successful management of patients with recurrent abdominal wall HG-ESS requires interdisciplinary and interprofessional teamwork. Multi-centre prospective trials are required to develop a guideline of optimal treatment for the disease entity, particularly the recurrence. |
Databáze: | OpenAIRE |
Externí odkaz: |